Cancer Biomarkers Funding Opportunities
| Title |
Announcement # |
Expiration Date | Activity Code | Contact |
|---|---|---|---|---|
| Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions | NOT-CA-20-044 | 05/08/2023 | Richard Mazurchuk, Ph.D | |
| Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | NOT-CA-20-067 (R01 Clinical Trial Not Allowed) | 01/08/2023 | R01 | Matthew Young, Ph.D. |
| Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | NOT-CA-21-028 | 01/08/2024 | Natalie Abrams, Ph.D. | |
| Notice to Extend Expiration Date for PAR-20-276: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | NOT-CA-22-092 (R01 Clinical Trial Not Allowed) | 09/08/2022 | R01 | Wendy Wang, Ph.D., M.Sc. |
| Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | PAR-20-053 (R01 Clinical Trial Not Allowed) | 01/08/2023 | R01 | Matthew Young, Ph.D. |
| Co-infection and Cancer | PAR-20-062 (R01 Clinical Trial Not Allowed) | 01/08/2023 | R01 | Jo Ann Rinaudo, Ph.D. |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems | PAR-20-155 (R01 Clinical Trial Optional) | 09/08/2022 | R01 | Richard Mazurchuk, Ph.D. |
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-276 (R01 Clinical Trial Not Allowed) | 01/08/2023 | R01 | Wendy Wang, Ph.D., M.Sc. |
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-277 (R21 Clinical Trials Not Allowed) | 09/08/2022 | R21 | Wendy Wang, Ph.D., M.Sc. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) | 10/11/2023 | UH2, UH3 | Lynn Sorbara, Ph.D. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-20-314 (UH3 Clinical Trials Not Allowed) | 10/11/2023 | UH3 | Lynn Sorbara, Ph.D. |
| Pancreatic Cancer Detection Consortium: Research Units | PAR-21-334 (U01 Clinical Trial Optional) | 06/12/2024 | U01 | Sharmistha Ghosh-Janjigian, Ph.D. |
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit | PAR-21-335 (U24 Clinical Trial Not Allowed) | 06/12/2024 | U24 | Sharmistha Ghosh-Janjigian, Ph.D. |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-22-099 (R01 Clinical Trial Optional) | 05/08/2025 | R01 | Richard Mazurchuk, Ph.D. |